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Abstract The aim of this study was to assess the preva-
lence of incomplete distal renal tubular acidosis (idRTA) in
men with recurrent calcium nephrolithiasis and its potential
impact on bone mineral density. We conducted a retro-
spective analysis of 150 consecutive, male idiopathic
recurrent calcium stone formers (RCSFs), which had origi-
nally been referred to the tertiary care stone center of the
University Hospital of Berne for further metabolic evalua-
tion. All RCSFs had been maintained on a free-choice diet
while collecting two 24-h urine samples and delivered sec-
ond morning urine samples after 12 h fasting. Among 12
RCSFs with a fasting urine pH [5.8, a modified 3-day
ammonium chloride loading test identified idRTA in 10
patients (urine pH [5.32, idRTA group). We matched to
each idRTA subject 5 control subjects from the 150 RCSFs,
primary by BMI and then by age, i.e., 50 patients, without
any acidification defect (non-RTA group) for comparative
biochemistry and dual energy X-ray absorptiometry
(DEXA) analyses. The prevalence of primary idRTA among
RCSFs was 6.7% (10/150). Patients with idRTA had sig-
nificantly higher 2-h fasting and 24-h urine pH (2-h urine pH:
6.6 ± 0.4 vs. 5.2 ± 0.1, p = 0.001; 24-h urine pH:
6.1 ± 0.2 vs. 5.3 ± 0.3, p = 0.001), 24-h urinary calcium
excretion (7.70 ± 1.75 vs. 5.69 ± 1.73 mmol/d, p = 0.02),
but significantly lower 24-h urinary urea excretion (323 ± 53
vs. 399 ± 114 mmol/d, p = 0.01), urinary citrate levels
(2.32 ± 0.82 vs. 3.01 ± 0.72 mmol/d, p = 0.04) and renal
phosphate threshold normalized for the glomerular filtration
rate (TmPO4/GFR: 0.66 ± 0.17 vs. 0.82 ± 0.21, p = 0.03)
compared to non-RTA patients. No significant difference in
bone mineral density (BMD) was found between idRTA and
non-RTA patients for the lumbar spine (LS BMD (g/cm2):
1.046 ± 0.245 SD vs. 1.005 ± 0.119 SD, p = 0.42) or
femoral neck (FN BMD (g/cm2): 0.830 ± 0.135 SD vs.
0.852 ± 0.127 SD). Thus, idRTA occurs in 1 in 15 male
RCSFs and should be sought in all recurrent calcium neph-
rolithiasis patients. Bone mineral density, however, does not
appear to be significantly affected by idRTA.
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Abbreviations
idRTA Incomplete distal renal tubular acidosis
Non-RTA Non-idRTA recurrent stone formers
BMD Bone mineral density
LS Lumbar spine
FN Femoral neck
DEXA Dual energy X-ray absorptiometry
SD Standard deviation
Introduction
The skeleton serves as a reservoir of labile calcium that can
be mobilized in response to humoral mechanisms for the
defense of blood pH and the maintenance of the ionic
calcium concentration. Several reports have underlined the
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negative impact of chronic metabolic acidosis on bone
mineral composition. Studies by others and us have sug-
gested a link between renal stone formation and osteopo-
rosis [1–4].
Distal renal tubular acidosis is a syndrome of systemic
hyperchloremic acidosis with alkaline urine pH, hypocit-
raturia and hypercalciuria due to reduced secretion of H?
ions by the cells of the collecting tubules [5, 6]. Overt
metabolic acidosis in distal renal tubular acidosis contrib-
utes as a predisposing factor to recurrent nephrolithiasis
and bone loss [7, 8]. In contrast, patients with incomplete
distal renal tubular acidosis (idRTA) have a persistently
high urine pH, but are able to maintain net acid excretion
under basal conditions. Thus, idRTA does not manifest in
overt systemic acidosis, but may cause recurrent positive
acid loads in periods of increased protein intake or cata-
bolic stress triggering alkali release from the bone and thus
leading to greater bone resorption [9, 10]. Patients with
idRTA frequently suffer from recurrent nephrolithiasis,
mainly with calcium phosphate stones, due to the combi-
nation of hypercalciuria, low urine citrate, and high
urine pH which favors calcium phosphate crystallization
[11].
Studies on an association between idRTA and calcium
nephrolithiasis are scarce. Population-based studies repor-
ted incidence rates of idRTA of 2–8% in patients with
nephrolithiasis, but were not able to establish a correlation
between idRTA and low bone mineral density (BMD) [12,
13]. In patients with reduced bone mass, however, preva-
lences of idRTA as high as 22% have been reported in
smaller studies, and a strong relationship between osteo-
porosis or reduced BMD and idRTA has been described in
adults [10, 14]. In children, idRTA is known to cause
skeletal growth retardation [15].
The aim of this study was to retrospectively assess the
prevalence of idRTA in men with recurrent calcium
nephrolithiasis and its potential impact on bone mineral
density.
Materials and methods
Study population
After institutional review board approval, a retrospective
analysis of 150 consecutive, male idiopathic recurrent
calcium stone formers (RCSFs) who had originally been
referred to the tertiary care stone centre of the University
Hospital of Berne for further metabolic evaluation was
performed. An RCSF was defined as a person who had
passage or had had removal of at least two calcium-con-
taining stones, established by either by stone analysis or
conventional radiogram findings.
RCSFs with a history of hyperthyroidism, hyperpara-
thyroidism or sarcoidosis were excluded. Past and present
smoking status, alcohol intake and corticosteroid use were
documented, and the patients’ weight and height were
recorded. According to our standard diagnostic protocol
[11], all RCSFs had been maintained on a free-choice diet
while making two 24-h urine collections (in the absence of
urinary tract infections).
Among 12 RCSFs with urine pH values[5.8 after 12 h
of fasting, a modified 3-day ammonium chloride loading
test (see biochemistry) had identified idRTA in 10 patients
who formed the idRTA group. We matched to each idRTA
subject 5 control subjects from the above-mentioned ori-
ginal 150 RCSFs, primary by BMI (due to the known
influence of weight on bone mineral density) and then by
age, i.e., 50 patients without an acidification defect.
These 50 RCSFs served as a non-RTA group for com-
parative laboratory and densitometric analyses. The exact
findings regarding stone composition were known in 9/10
idRTA patients (7 calcium phosphate/calcium oxalate
stones, 2 calcium oxalate stones) and in 24/50 control
patients (22 calcium oxalate, 2 calcium oxalate/calcium
phosphate). In the remaining patients, diagnosis was based
on the radio-opaque stone findings from conventional
radiograms.
Biochemistry
Plasma from fasting venous blood was analyzed for cre-
atinine, total calcium, phosphate and alkaline phosphatase
activity using autoanalyzer techniques. In whole blood,
ionized calcium was measured by an ion-selective elec-
trode (Ciba Corning Diagnostics Corp., Medford, MA,
USA) and venous bicarbonate by a Ciba Corning 278 blood
gas system immediately after sampling without compres-
sion. None of the study subjects had systemic acidosis
based on the venous BGA analysis. Serum intact PTH
(normal values 10–65 pg/mL) and 25-OH-Vitamin D
(normal range 6–40 ng/mL) were measured using radio-
immunoassay (Nichols Institute, San Juan Capistrano, CA,
USA). All study subjects had two 24-h urine collection
under free-choice diet. On evaluation day sampling of
venous blood and a 2-h fasting urine after 12 h without
eating and 8 h without drinking were performed in all
patients (Fig. 1). In 2-h fasting urine (2nd morning urine),
pH was measured by a Metrohm 654 pH-meter (Metrohm,
Herisau, Switzerland). Fasting urine was analyzed for
calcium and creatinine using autoanalyzer techniques, and
hydroxyproline was determined using a kit (Organon
Teknika, Boxtel, The Netherlands). Patients with an uri-
nary pH[5.8 in the 2-h fasting urine underwent a modified
ammonium chloride loading test using a lower dose of
ammonium chloride, as originally established by Hess et al.
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[11]. In 24-h urine, creatinine and calcium were measured
by autoanalyzer techniques, and citrate was determined
using the citrate lyase method [11]. The 24-h urine samples
were collected in a 3-l plastic bottles containing 10 g boric
acid as preservative. In collaboration with the central lab-
oratory of the University Hospital in Berne, we had pre-
viously extensively studied the influence of 10 g of boric
acid on pH from 24-h urine collections in the 3-l urine
containers. We found that pH values were not significantly
altered. All individual 24-h urine values are the mean of
two urine collections.
The modified, ‘‘more physiologic’’ ammonium chloride
loading test consisted of sampling venous blood and 2-h
fasting urine after 12 h without eating and 8 h without
drinking on day 0. From then on, ammonium chloride (total of
0.05 g/kg body weight/day or 0.95 mEq/kg body weight/day)
was added to the free-choice diet for 3 days, given in capsules
(Streuli Pharma, Uznach, Switzerland) in three divided doses
20 min before each meal. On day 3, sampling of fasting
venous blood and 2-h urine was repeated.
Bone mineral density measurements
We routinely perform DEXA scans on recurrent calcium
stone formers during metabolic evaluation. 50 control
patients, without any acidification defect, were selected
(non-RTA group) for comparative DEXA analyses versus
the idRTA group. BMD measurements of the lumbar spine
(LS; L2–L4) and of the non-dominant (or non-fractured)
femoral neck (FN) were assessed by DEXA (Hologic,
Bedford, MA, USA).
Scans had been performed according to the manufac-
turer’s guidelines and analyzed according to ISCD rules
with respect to exclusion of vertebrae that had been
affected by local structural changes or artefacts [REF
International Society for Clinical Densitometry (ISCD)
official positions 2007; available at http://www.iscd.org/
Visitors/positions/officialPositionsText.cfm. BMD was
expressed in grams per square centimeter of hydroxyapatite
and as T-scores (standard deviation [SD] from the mean of
a healthy young reference population) and Z-scores (SD
from the mean of the reference population of the same
age). When vertebrae had to be excluded, the BMD of the
remaining vertebrae was used to derive the T- and Z-scores,
i.e., three vertebrae instead of four, or two instead of three,
were used, respectively. Local normal values were derived
from 400 healthy white women and men living in the area
of Berne, Switzerland. Quality control was performed daily
(anthropometric spine phantom supplied by the manufac-
turer) with an overall precision error of 0.3% in vitro and a
mean precision error in our hands of 1.1% in vivo.
Statistical analysis
The data are presented as mean ± SD. Normality of the
data was assessed by Kolmogorov–Smirnov test. Student’s
t test was used as appropriate for the comparison of the
group means and proportions. Statistical analyses were
done using Prism 4.0; GraphPad Software Inc., San Diego,
CA. A p value \0.05 was considered statistically
significant.
Results
Two-hour fasting urine pH, measured in all 150 male
RCSFs, exceeded 5.8 in 12 cases. Ammonium chloride
loading was abnormal in 10 cases, i.e., the fasting urine pH
after ammonium chloride loading did not fall below 5.32
(Fig. 2). In the absence of systemic metabolic acidosis
upon ammonium chloride loading, these 10 RCSFs were
diagnosed as having idRTA. Thus, the prevalence of
idRTA in 150 male RCSFs was 6.7%.
Biometric data and serum and urinary results in idRTA
and non-RTA groups are summarized in Table 1 and
Fig. 3. There were no significant differences between the
Fig. 1 Protocol for urine
evaluation of recurrent renal
stone formers. All study
subjects had two 24-h urine
collection under free-choice diet
(24-h urine-1 and 24-h urine-2:
24-h urine collections no. 1 and
2). On evaluation day a 2-h
fasting urine after 12 h without
eating and 8 h without drinking
were performed in all patients
(2-h urine). Patients with an
urinary pH [5.8 in the 2-h
fasting urine underwent the
modified ammonium chloride
loading test, as previously
established by Hess et al. [11]
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two groups, except for higher 2-h fasting and 24-h urine pH
(2-h urine pH: 6.6 ± 0.4 vs. 5.2 ± 0.1, p = 0.001; 24-h
urine pH: 6.1 ± 0.2 vs. 5.3 ± 0.3, p = 0.001), 24-h uri-
nary calcium excretion (7.70 ± 1.75 vs. 5.69 ± 1.73
mmol/d, p = 0.02), but significantly lower 24-h urinary
urea excretion (323 ± 53 vs. 399 ± 114 mmol/d, p = 0.01),
urinary citrate levels (2.32 ± 0.82 vs. 3.01 ± 0.72
mmol/d, p = 0.04) and renal phosphate threshold normal-
ized for the glomerular filtration rate (TmPO4/GFR:
0.66 ± 0.17 vs. 0.82 ± 0.21, p = 0.03) compared to non-
RTA patients.
Densitometric data are given in Table 2. Bone mineral
density in g/cm2, Z-scores as comparative references values
and T-scores did not differ significantly between the idRTA
and the non-RTA groups, either for the LS or FN. In par-
ticular, the clinically most widely used T-scores were not
different, either for the LS (-0.4 ± 1.8 in idRTA vs.
-0.7 ± 0.8 in non-RTA, p = 0.41) or FN (-0.9 ± 1.1 in
idRTA vs. -0.7 ± 1.0 in non-RTA, p = 0.60). Figure 4
shows a box-plot of T- and Z-scores for the LS (L2–L4) and
FN for both groups.
Discussion
This study investigated two issues: (1) the prevalence of
idRTA in male recurrent calcium stone formers (RCSFs);
and (2) the impact of idRTA on bone mineral density
(BMD).
The prevalence of RTA in the general population in
Switzerland is not known because no epidemiological
study has ever investigated this issue. We found that 6.7%
of 150 male RCSFs had idRTA, i.e., 1 out of 15 male
RCSFs can be expected to have idRTA. This is similar to
the findings of previous epidemiological studies in endemic
areas with a known high prevalence of idRTA [13, 16]. We
thus believe that idRTA is generally underdiagnosed due to
the lack of routine screening, including ammonium chlo-
ride loading, in patients with recurrent nephrolithiasis or
suspected low bone mineral density. Our study also con-
firmed the well-known increased urinary calcium and
decreased urinary citrate excretion in RCSFs with idRTA
[11]. The difference in urinary citrate is statistically sig-
nificant, although not in the expected magnitude. This may
be attributable to the limited sample size of idRTA patients
and due to the fact that urinary citrate in both groups was
performed under free choice diet and not under standard-
ized conditions.
Chronic acid retention in idRTA increases the release of
calcium phosphate from bone and reduces tubular reab-
sorption of calcium and phosphate. As a consequence,
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Fig. 2 Line diagram of 2-h fasting urine pH under free choice diet
and after NH4Cl test in idRTA subjects
Table 1 Demographic and laboratory data of idRTA and non-RTA
groups
Groups idRTA
(n = 10)
Non-RTA
(n = 50)
p value
Age (years) 53 ± 12 46 ± 11 0.10
BMI (kg/cm2) 26 ± 3 26 ± 3 0.97
S-Bicarbonate (mmol/l) 26 ± 3 28 ± 2 0.15
S-Bicarbonate after
NH4Cl (mmol/l)
23 ± 1
S-creatinin (mmol/l) 86.4 ± 13 92.3 ± 14 0.28
S-total Ca2 (mmol/l) 2.3 ± 0.1 2.4 ± 0.1 0.10
S-ion Ca2 (mmol/l) 1.2 ± 0.1 1.3 ± 0.1 0.22
S-phosphate (mmol/l) 0.9 ± 0.1 0.9 ± 0.2 0.82
S-Alk-Phos (U/l) 69 ± 13 78 ± 24 0.27
PTH (pg/ml) 27 ± 13 31 ± 11 0.32
S-25(OH)VitD3
(nmol/ml)
92 ± 6 71 ± 23 0.06
2-h urine pH fasting 6.6 ± 0.4 5.2 ± 0.1 0.001
2-h urine pH after NH4Cl 5.8 ± 0.3
24-h urine pH 6.1 ± 0.2 5.3 ± 0.3 0.001
U-HProl/creat
(nmol/mmol)
0.01 ± 0.01 0.01 ± 0.01 0.98
U-Ca (mmol/d) 7.70 ± 1.75 5.69 ± 1.69 0.02
U-citrate (mmol/d) 2.32 ± 0.82 3.01 ± 0.72 0.04
U-anion-gap 78 ± 21 67 ± 24 0.29
U-uric acid (lmol/d) 2,982 ± 1,297 3,397 ± 1,016 0.38
U-urea (mmol/d) 323 ± 53 399 ± 114 0.01
TmPO4/GFR 0.66 ± 0.17 0.82 ± 0.21 0.03
Bold values indicate p \ 0.05 was considered statistically significant
S serum, S-ion Ca2 serum ionized calcium concentration, S-Alk-Phos
serum alkaline phosphatase, PTH serum parathormone, S-
25(OH)VitD3 serum 25(OH)Vitamin D3, U urinary, 2-h fasting urine
pH under free-choice diet, 24-h urine pH under free-choice diet, 2-h
urine pH after NH4Cl ammonium chloride loading test, U-HProl/crea
urinary hydroxyproline/creatinine ratio, U-Ca 24-h urinary calcium
excretion, U-citrate: 24-h urinary citrate excretion, TmPO4/GFR:
renal phosphate threshold normalized for the glomerular filtration rate
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hypercalciuria, a known risk factor for stone formation
develops and the precipitation of calcium phosphate crys-
tals is further favored by the persistently high urine pH in
idRTA [6, 17]. Moreover, idRTA reduces the urinary
excretion of citrate, because intracellular acidosis in
proximal renal tubular cells—as in idRTA—favors the
tubular reabsorption of citrate. Because citrate is an
important inhibitor of the precipitation of stone-forming
calcium salts in urine, hypocitraturia together with hyper-
calciuria and elevated urinary pH additionally predispose
patients with idRTA to calcium phosphate stone formation
[6]. Similarly, chronic dietary acid loads were shown to
result in significant and reversible negative calcium bal-
ance [18]. On the other hand, partial neutralization of an
acidogenic western diet with exogenous potassium citrate
or potassium bicarbonate can improve calcium balance,
reduce bone reabsorption, and increase the rate of bone
formation [19, 20].
Our study was not able to detect a significant impact of
idRTA on BMD in the LS or FN. According to BMD
values and T- and Z-scores, the skeletal scores were not
significantly different between our idRTA and non-RTA
groups. Findings on the clinical nature and impact of id-
RTA on bone density are inconsistent. In accordance with
our findings, a recent report by Pongchaiyakul et al. [13]
found no association between idRTA and lower bone mass
in a community-based study on endemic RTA in Thailand.
After a follow-up period of 24 months, no significant dif-
ference in bone loss between idRTA subjects and controls
was found, providing additional support for the hypothesis
that idRTA may have at most a minor impact on BMD.
Considering the differences in genetic background, popu-
lation characteristics and dietary habits, however, it may be
inappropriate to extrapolate findings from Thailand to our
Swiss study population.
Renal tubular dysfunction after kidney transplantation
inducing RTA has been described by Keven et al. [21] in
over 30% of allograft recipients. Nevertheless, the preva-
lence of osteopenia or osteoporosis appeared not to be
different between allograft recipients with RTA and those
without. A major limitation of this study, however, was the
lack of acid loading tests and the absence of information on
a history of renal osteodystrophy or pre-transplant BMD
status.
The studies by Weger et al. [10] and Deutschmann et al.
[14] in patients with osteoporosis contrast sharply with our
findings and those of others. The incidence of idRTA in
these studies was up to 22%. However, there was a fun-
damental difference from our approach and that of others:
both studies did not evaluate kidney stone patients, but
selected primarily patients with osteoporosis for further
evaluation of osteoporosis risk factors. Indeed, Deutsch-
mann et al. [14] found a significant correlation between the
number of identified risk factors and severity of bone dis-
ease, but did not find a direct correlation between idRTA
and BMD. Furthermore, they did not measure urinary
excretion of citrate before or after ammonium chloride
loading.
We offer a hypothetical explanation for the differences
observed in BMD between idRTA patients primarily
affected by kidney stone disease and those suffering from
osteoporosis. Chronic acid retention in idRTA might
mobilize extracellular buffers in two different ways: on the
one hand, renal stone patients with idRTA might prefer-
entially buffer retained acid in renal tubular cells, resulting
in a rise in citrate uptake (hypocitraturia) and reduced renal
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Fig. 3 Box-plots of 24-h
urinary citrate excretion and
from 2-h fasting urine pH, both
for idRTA and non-RTA groups
Table 2 Densitometric characteristics of idRTA and non-RTA
groups
idRTA (n = 20) Non-RTA (n = 50) p value
Lumbar spine
BMD (g/cm2) 1.046 ± 0.245 1.005 ± 0.119 0.42
T-score (SD) -0.4 ± 1.8 -0.7 ± 0.8 0.41
Z-score (SD) 0.3 ± 1.8 -0.1 ± 0.9 0.26
Femoral neck
BMD (g/cm2) 0.830 ± 0.135 0.852 ± 0.127 0.61
T-score (SD) -0.9 ± 1.1 -0.7 ± 1.0 0.60
Z-score (SD) 0.3 ± 1.2 0.3 ± 1.5 0.92
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tubular calcium reabsorption (hypercalciuria); on the other
hand, osteoporosis patients with idRTA might rather use
bone tissue for extracellular buffering, which in turn would
result in a progressive loss of bone mass.
In conclusion, one in 15 male recurrent calcium stone
formers exhibit idRTA. However, idRTA in men with
recurrent calcium stone disease does not appear to signif-
icantly affect BMD in the lumbar spine and femoral neck in
comparison with stone formers without idRTA.
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